 |
|
Clinical Trials
|
|
Macular Degeneration
|
|
Disease/ Subspecialty:
Macular Degeneration - Low Vision
Principal Investigator:
M. Bowes Hamill, M.D.
Contact:
email Low_Vision-trials@bcm.tmc.edu
or call (713)798-3044
Enrollment:
Yes
Sponsor:
Vision Care Ophthalmics
Title:
Safety and efficacy assessment of the implantable miniature telescope (IMT) Phase
II.
IRB Protocol #:
H-12755 |
 |
Disease/ Subspecialty:
Macular Degeneration
Principal Investigator:
William Mieler, M.D.
Contact:
email Macular-D-Trials@bcm.tmc.edu
or call (713)798-4037
Enrollment:
Yes
Sponsor:
QLT, Inc.
Title:
A randomized placebo-controlled, double-masked, mulit-center Phase III study of the effect of Visudyne therapy in occult with no classic subfoveal choroidal neovascularation (CNV) secondary to age-related macular degeneration (AMD).
IRB Protocol #:
H-11972 |
|
Disease/ Subspecialty:
Macular Degeneration
Principal Investigator:
Eric Holz, M.D.
Contact:
email Macular-D-Trials@bcm.tmc.edu
or call (713)798-4037
Enrollment:
No
Sponsor:
none
Title:
Intravitreal injection or Triamcinolone Acetonide in exudative age-related macular degeneration.
IRB Protocol #:
H-9570
|
|
Disease/ Subspecialty:
Macular Degeneration
Principal Investigator:
William Mieler, M.D.
Contact:
email Macular-D-Trials@bcm.tmc.edu
or call (713)798-4037
Enrollment:
No
Sponsor:
Eyetech Pharmaceuticals
Title:
A Phase II/III randomized, double-masked, controlled, dose-ranging,multi-center comparative trial in parallel groups to establish the safety and efficacy of introvitreal injections of EVE001(anit-vegf Pegylated aptamer) given every 6 weeks for 54 weeks in patients with excudative age-related macular degeneration (AMD).
IRB Protocol #:
H-13043
|
|
Disease/ Subspecialty:
Macular Degeneration
Principal Investigator:
Eric Holz, M.D.
Contact:
email Macular-D-Trials@bcm.tmc.edu
or call (713)798-4037
Enrollment:
Yes
Sponsor:
GenVec Inc.
Title:
An open-label, phase I, single administration, dose-escalation study of AD(GV)PEDF .11D in neovascular-related macular degeneration (AMD).
IRB Protocol #:
H-11081
|
|
Disease/ Subspecialty:
Macular Degeneration
Principal Investigator:
William Mieler, M.D.
Contact:
email Macular-D-Trials@bcm.tmc.edu
or call (713)798-4037
Enrollment:
Yes
Sponsor:
Gen entech, Inc.
Title:
A phase III, multicenter, randomized, double-masked sham injection-controlled study of the efficacy and safety of Rhufab V2 (Ranibizumab) in subjects with minimally classic or occult subfoveal neovascular age-related macular degeneration.
IRB Protocol #:
H-13387
|
|
|
